PAUL STODDARD: Open Payments
NPI 1396478491 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$331 in 12 payments from 8 companies in 2025. Trend: 2023 $77 · 2024 $369 · 2025 $331
Food & beverage: $231Education: $100
| Company | Payments | Amount |
|---|---|---|
| Astellas Pharma US Inc | 2 | $121 |
| Sumitomo Pharma America, Inc. | 3 | $67 |
| TOLMAR, INC. | 2 | $29 |
| Dendreon Pharmaceuticals LLC | 1 | $29 |
| ABC Home Medical Supply, Inc. | 1 | $26 |
| Janssen Biotech, Inc. | 1 | $24 |
| Verity Pharmaceuticals Inc. | 1 | $19 |
| Innovation Technologies Inc | 1 | $15 |
Products named: GEMTESA, JATENZO, PROVENGE, ERLEADA, Xtandi, ORGOVYX, Trelstar, IRRISEPT.
Industry payments across TX — which companies pay providers there.
